In conclusion, although KRT17 has been studied in many types of cancer, including BC, our research found that high KRT17 expression correlated with good survival in BC patients with higher HER2 expression but poor survival in patients with lower HER2 expression. The gene discussed is ERBB2; the disease is breast cancer.